Clearside Biomedical
CLSD
CLSD was delisted on the 28th of November, 2025.
54 hedge funds and large institutions have $9.62M invested in Clearside Biomedical in 2023 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 10 increasing their positions, 13 reducing their positions, and 5 closing their positions.
100% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 5
16% more call options, than puts
Call options by funds: $136K | Put options by funds: $117K
8% more funds holding
Funds holding: 50 → 54 (+4)
6% more capital invested
Capital invested by funds: $9.09M → $9.62M (+$532K)
0.02% less ownership
Funds ownership: 0.95% → 0.93% (-0.02%)
23% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$139K |
| 2 |
TC
TownSquare Capital
Provo,
Utah
|
+$126K |
| 3 |
Stifel Financial
St. Louis,
Missouri
|
+$54.9K |
| 4 |
VF
Virtu Financial
New York
|
+$38.8K |
| 5 |
Millennium Management
New York
|
+$38.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$141K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$118K |
| 3 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
-$104K |
| 4 |
LNC
Lincoln National Corp
Radnor,
Pennsylvania
|
-$96K |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$91.7K |
CLSD Hedge Fund Activity: Q2 2023 in Review
54 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Clearside Biomedical (CLSD) for Q2 2023, worth a combined $9.62M — up 5.9% from $9.09M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new CLSD positions and 5 closed out — a net gain of 5 holders — while 10 added to existing stakes and 13 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $139K. The largest seller was Renaissance Technologies, cutting an estimated $141K.
- 54 institutional investors held Clearside Biomedical (CLSD) as of Q2 2023, up from 50 in Q1 2023.
- Funds reported $9.62M of Clearside Biomedical stock for Q2 2023, up 5.9% quarter-over-quarter.
- 10 funds opened new Clearside Biomedical positions in Q2 2023 and 5 closed out, a net change of +5 holders.
- The largest Clearside Biomedical buyer in Q2 2023 was Morgan Stanley, an estimated $139K added.
- The largest Clearside Biomedical seller in Q2 2023 was Renaissance Technologies, an estimated $141K sold.
Based on aggregated 13F filings for Q2 2023.